Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Hold” from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been given an average recommendation of “Hold” by the eight research firms that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $24.80.

Several research firms have commented on AMLX. Robert W. Baird downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Monday, March 11th. Leerink Partnrs downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Monday, June 24th. Finally, SVB Leerink downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th.

Amylyx Pharmaceuticals Trading Down 2.8 %

NASDAQ AMLX opened at $1.72 on Friday. The firm’s fifty day moving average price is $1.79 and its two-hundred day moving average price is $7.71. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $25.48. The firm has a market capitalization of $116.98 million, a P/E ratio of -1.61 and a beta of -0.64.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. The firm had revenue of $88.64 million for the quarter, compared to the consensus estimate of $113.26 million. During the same period last year, the company posted $0.02 earnings per share. On average, research analysts anticipate that Amylyx Pharmaceuticals will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its stake in Amylyx Pharmaceuticals by 52,575.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after buying an additional 15,247 shares in the last quarter. Quest Partners LLC acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter worth about $89,000. China Universal Asset Management Co. Ltd. grew its stake in Amylyx Pharmaceuticals by 351.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,815 shares of the company’s stock worth $115,000 after buying an additional 6,085 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Amylyx Pharmaceuticals by 69.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,389 shares of the company’s stock worth $153,000 after buying an additional 4,255 shares in the last quarter. Finally, Arizona State Retirement System acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter worth about $166,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.